|
Jul 30
|
Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
|
|
Jul 28
|
Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy
|
|
Jul 24
|
Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study
|
|
Jun 23
|
Alterity Therapeutics to Provide Corporate Update in Fireside Chat
|
|
Apr 10
|
Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
|
|
Apr 3
|
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
|
|
Mar 12
|
3 Promising ASX Penny Stocks With Market Caps Over A$20M
|
|
Mar 10
|
Alterity Therapeutics (ATHE): Among the Best Australian Stocks to Buy According to Billionaires
|
|
Feb 10
|
Alterity Therapeutics Raises A$40.0 million in Placement
|
|
Sep 30
|
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
|
|
Jul 31
|
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
|
|
Jul 24
|
Alterity Therapeutics to Present at MST Financial Webinar
|
|
Jun 12
|
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
|
|
Jan 29
|
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
|
|
Dec 21
|
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
|
|
Dec 5
|
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
|
|
Dec 4
|
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
|
|
Dec 4
|
Biotech Alterity Jumps On Upbeat Parkinson's Treatment Clinical Trial Data
|
|
Dec 4
|
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
|
|
Nov 27
|
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy
|